Ring Is Alcohol Moiety Patents (Class 514/548)
-
Publication number: 20100330212Abstract: A skin-sensitizing formulation is provided in an edible, softgel pill. A person engaged in a sexual activity bites down on the pill, thereby effectuating the oral release of the skin-sensitizing formulation. This allows the skin-sensitizing formulation to be spread to a sexual partner, on any part of the skin or sexual region of the body preferably through oral contact with the partner. The skin-sensitizing substance is spread to the partner directly on the skin or through oral contact or beneath a condom worn by the partner. The skin-sensitizing formulation may include an essential mint oil, analog or derivative, and may further includes an enhancer, rubefacient, counterirritant, anesthetic, K-Opoid Receptor activator, or TRPM8 activator. Various inactive ingredients are also disclosed.Type: ApplicationFiled: June 29, 2010Publication date: December 30, 2010Inventor: Amy Grosso-Piacentino
-
Publication number: 20100330064Abstract: Compounds of formula (I): wherein: R1 represents a hydrogen atom or a group of formula COR4, or R1 represents a group of formula (A): R2 represents a group of formula NR5R6, or R2 represents a nitrogen-containing heterocyclic group, an aryl group or a heteroaryl group, R3 represents a hydrogen atom or an alkyl group, m represents an integer between 1 and 6 inclusive, n represents 0, 1 or 2, their optical isomers, and also addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in treating and/or preventing thrombotic events.Type: ApplicationFiled: June 25, 2010Publication date: December 30, 2010Applicants: LES LABORATOIRES SERVIER, L'INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN, LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, L'UNIVERSITE DE ROUENInventors: Philippe Gloanec, Guillaume De Nanteuil, Jean-Gilles Parmentier, Anne-Françoise Guillouzic, Tony Verbeuren, Alain Rupin, Philippe Mennecier, Marie-Odile Vallez, Jean-Charles Quirion, Philippe Jubault, Nicolas Boyer
-
Patent number: 7858602Abstract: A method for the treatment and prophylaxis of conditions of aging due oxidative stress and as growth factors of stem cells. Such conditions due to oxidative stress are associated with a decreased presence of one or more cell-specific carbonic anhydrase enzymes in the tissue of a subject. Such conditions include but are not limited to alzheimer's disease, parkinson's disease, multiple sclerosis, autism, lou gehrig's disease, huntington's disease, diabetes mellitus, amyloid diseases, atherosclerosis, arthritis, osteoporosis, cystic fibrosis. The method comprises administering to the patient a pharmaceutically effective, non-toxic amount of one or more compounds that increases the presence of one or more Carbonic Anhydrase Isozymes whose levels have been reduced in the subject.Type: GrantFiled: May 12, 2007Date of Patent: December 28, 2010Inventor: Victorio C. Rodriguez
-
Patent number: 7851510Abstract: The present invention relates to compounds of general formula (1): in which, independently of each other, R1 and R2 represent: —OH, or —CH2—O—R3, or —CH2—S—R3, or R3, R4, R5 and R6 representing, independently of each other, —H or a carbon-containing group with 1 to 10 carbon atoms, saturated or unsaturated, optionally substituted with one or more heteroatomic groups. The invention also relates to pharmaceutical compositions containing these compounds, and their uses, in particular in the context of the treatment of cancer.Type: GrantFiled: January 6, 2005Date of Patent: December 14, 2010Assignees: Centre National de la Recherche Scientifique (C.N.R.S.), Institut National de la Sante et de la Recherche Medicale (I.N.S.E.R.M)Inventors: Vi-Thuy Dao, Jean De Gunzburg, Robert Michelot, Oliver Christophe De Mil
-
Publication number: 20100310615Abstract: The invention relates to compositions comprising pholyphenol derivatives, characterised in that said polyphenols contain monomers, oligomers or polymers with units having formula (I), said units being characterised by the simultaneous presence of a resorcinol nucleus (nucleus A) and a para-phenol nucleus (nucleus B) which are interconnected by a carbon bond C, said derivatives being over-activated, in respect of the nucleophilic power thereof, by alkylation of at least one phenol function of each constituent monomer unit and stabilised by sterification by mixtures of fatty acids in proportions reflecting those of vegetable oils formed mainly by unsaturated fatty acids of all of the other phenol functions. The invention is suitable for use in cosmetics, dietetics and therapeutics.Type: ApplicationFiled: November 17, 2008Publication date: December 9, 2010Inventor: Joseph Vercauteren
-
Publication number: 20100310508Abstract: The onset ratios and pathological conditions of collagen-induced arthritis and adjuvant arthritis in model mice and rats, respectively, were successfully ameliorated by topically expressing the cyclin-dependent kinase inhibitors p161nk4a and p21Cip1 in articular tissues using adenoviral vectors. In the synovial cells of CDKI-transduced mice, expression of inflammatory cytokines was inhibited. Described are the use of the p21Cip1 protein for inhibiting abnormal proliferation of synovial tissues, inflammation in synovial tissues and/or expression of inflammatory cytokines in synovial tissues; the p21Cip1 gene; compounds promoting the activity or expression of the p21Cip1 protein; and pharmaceutical compositions containing these molecules. Also provided are method of screening for compounds participating in the abnormal proliferation of synovial tissues, inflammation in synovial tissues and/or the expression of inflammatory cytokines in synovial tissues targeting the p21Clip1 protein.Type: ApplicationFiled: June 1, 2010Publication date: December 9, 2010Inventors: Nobuyuki Miyasaka, Hitoshi Kohsaka
-
Publication number: 20100311833Abstract: A method of imparting a physiological cooling effect to a consumer product is disclosed. The method comprises formulating into the consumer product a composition comprising at least one lactoyl ester of menthyl lactate. Also disclosed is a method of providing physiological cooling by contacting skin or mucous membranes with the lactoyl ester compositions. Coolants comprising the lactoyl esters and additional coolants are also disclosed. The lactoyl esters are conveniently prepared from menthol and lactic acid.Type: ApplicationFiled: August 10, 2010Publication date: December 9, 2010Inventors: Mark B. Erman, Patrick J. Whelan, Joe W. Snow
-
Publication number: 20100303902Abstract: The invention relates to self emulsifying drug delivery system based compositions of rhein or diacerein, or salts or esters or prodrugs thereof which are bioequivalent to a 50 mg diacerein formulation marketed under the trade name Art 50®. The compositions exhibit no variability in fed and fasted state conditions. The compositions also result in significant reduction in side effects such as, soft stools effects as compared to Art 50®. The invention also relates to methods for preparing such compositions.Type: ApplicationFiled: September 27, 2008Publication date: December 2, 2010Inventors: Premchand Nakhat, Prashant Mandaogade, Girish Kumar Jain, Munish Talwar
-
Publication number: 20100305165Abstract: Disclosed herein are thiocolchicine derivatives suitable for use as muscle relaxants, methods of making the derivatives, and compositions comprising the derivatives.Type: ApplicationFiled: May 27, 2010Publication date: December 2, 2010Inventor: Rajesh Manchanda
-
Publication number: 20100285114Abstract: The invention relates to pharmaceutical compositions of rhein or diacerein, or salts or esters or prodrugs thereof which are bioequivalent to a 50 mg diacerein formulation marketed under the trade name Art 50®. The compositions exhibit no variability in fed and fasted state conditions. The compositions also result in significant reduction in side effects such as, soft stools as compared to Art 50®. The invention also relates to the methods for preparing such compositions.Type: ApplicationFiled: September 16, 2008Publication date: November 11, 2010Inventors: Rahul Dabre, Girish Kuamr Jain, Roshanlal Sandal, Vikrant Thakkar
-
Publication number: 20100280056Abstract: Methods are provided herein to determine if a subject is a candidate for treatment with an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR). The method includes determining the presence of at least one polymorphism in the HMGCR gene in a sample from a subject. The presence of at least one polymorphism indicates that the subject is a candidate for treatment with a statin, for example to decrease risk of or treat cancer, cardiovascular disease, diabetes, obesity, inflammatory disease, or auto-immune disease.Type: ApplicationFiled: November 4, 2008Publication date: November 4, 2010Inventors: Levy Kopelovich, Steven M. Lipkin, Gad Rennert, Stephen B. Gruber, Victor Moreno
-
Publication number: 20100273725Abstract: The present invention relates to photosensitizer compounds for use in cosmetic and therapeutic applications of photodynamic therapy. The compounds of the present invention are designed for topical application and are characterized by a low permeability to the stratum corneum (the outer skin layer of an individual) and/or a low allergenic potential. Surprisingly, such compounds have beneficial properties in the treatment of certain diseases and lack the undesired damages to healthy skin entailed by prior art compounds. ALA (5-aminolevulinic acid)-esters of body-owned, natural compound such as aminoacids, steroids, carbohydrades, alcohols are preferred, examples of photosensitizers of the present invention. The compounds of the present invention are used in the treatment of skin diseases such as psoriasis, sebaceous glands related conditions including acne, seborrhoic dermatitis, rosacea, skin cancer and precancer, as well as in cosmetic hair removal.Type: ApplicationFiled: December 12, 2008Publication date: October 28, 2010Inventors: Thomas Glanzmann, Jérôme Barge, Georges Wagnieres
-
Patent number: 7816347Abstract: A combination therapy is disclosed for treating or inhibiting cardiovascular or metabolic diseases or conditions through a combination of at least one inhibitor of neutral endopeptidase (=NEP), at least one inhibitor of the endogenous endothelin producing system and at least one HMG CoA reductase inhibitor. Pharmaceutical compositions are also described comprising NEP inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors and the use of these pharmaceutical composition in the prophylaxis or treatment of cardiovascular and/or metabolic disorders or diseases in mammals (including humans).Type: GrantFiled: December 14, 2005Date of Patent: October 19, 2010Assignee: Solvay Pharmaceuticals GmbHInventors: Klaus Witte, Dieter Ziegler, Matthias Straub, Paulus Antonius Remigius Koopman
-
Publication number: 20100256232Abstract: The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Subjects can be further treated by co-administering an EGFR inhibitor. The present application also relates to analyzing a sample with respect to levels of IGF-1R and EGFR and comparing levels of IGF-1R and EGFR to a control. Patients can be selected for treatment with a catecholic butane based on the assessment; optionally, patients can be further treated with an EGFR inhibitor, an IGF-1R inhibitor, or both.Type: ApplicationFiled: November 6, 2009Publication date: October 7, 2010Inventors: Thomas F. White, Edward F. Schnipper, Dan Hoth
-
Publication number: 20100240748Abstract: The present invention relates to novel tetrahydronaphthalen-2-ol derivatives, to pharmaceutical compositions comprising these compounds and to their use in therapy, in particular to their use for the manufacture of a medicament for the prevention or treatment of lower urinary tract symptoms, benign prostate hyperplasia, prostate cancer, hot flushes, anxiety, depression, breast cancer, medullary thyroid carcinoma, ovarian cancer, inflammatory bowel disease, arthritis, endometriosis, and colon cancer.Type: ApplicationFiled: March 11, 2010Publication date: September 23, 2010Inventors: Herman Thijs Stock, Neeltje Miranda Teerhuis, Gerrit Herman Veeneman
-
Publication number: 20100239669Abstract: Co-therapy of an anti-obesity agent, a statin, is disclosed along with fixed combinations thereof. Atorvastatin and orlistat are preferred as the various components.Type: ApplicationFiled: May 21, 2010Publication date: September 23, 2010Applicant: Scidose LLCInventor: Negeswara R. Palepu
-
Publication number: 20100234407Abstract: The present invention provides a preventive or therapeutic drug for a myeloma tumor and osteoclastic bone loss associating therewith, the drug containing as an active ingredient an osteopontin-production regulator or inhibitor; a screening method for a preventive or therapeutic drug for a myeloma tumor, characterized by determining osteopontin production regulatory or inhibitory effect; as well as a diagnostic kit for a myeloma tumor, characterized by including a reagent for measuring blood osteopontin level, and a diagnostic method.Type: ApplicationFiled: January 4, 2010Publication date: September 16, 2010Applicant: KOWA CO., LTD.Inventors: Yukihiko Saeki, Hideyuki Kobayashi, Yuichiro Tabunoki
-
Publication number: 20100222283Abstract: Methods are provided for treating and preventing renal disease in a subject by administering a gamma secretase inhibitor or a Notch pathway inhibitor to the subject.Type: ApplicationFiled: September 4, 2008Publication date: September 2, 2010Inventors: Katalin Susztak, Bernhard Bielesz, Thiruvur G. Niranjan
-
Publication number: 20100204254Abstract: The present invention discloses statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) consistently and significantly increased endothelial cell thrombomodulin protein and functional activity. Statins also abrogated the downregulation of thrombomodulin that occurs in response to radiation injury. These results indicate that preserving or restoring endothelial thrombomodulin expression and function by statins may be useful in a variety of disorders associated with widespread endothelial dysfunction such as sepsis, adult respiratory distress syndrome, and normal tissue radiation injury.Type: ApplicationFiled: January 29, 2010Publication date: August 12, 2010Applicant: The University of Arkansas for Medical SciencesInventors: Martin K. Hauer-Jensen, Louis M. Fink, Jawahar Lal Mehta, Junru Wang, Jacob Joseph
-
Publication number: 20100190730Abstract: The present invention relates to the application of 5-methyl-1,3-benzenediol or its derivatives represented by Formula I; wherein the constituent variables are as defined herein or pharmaceutical compositions thereof containing them in the preparation of medicines or functional foods. The present studies indicate that 5-methyl-1,3-benzenediol or its derivatives represented by Formula I, wherein the constituent variables are as defined herein or pharmaceutical compositions thereof containing them show more significant antidepressant effects than fluoxetine or imipramine.Type: ApplicationFiled: July 25, 2008Publication date: July 29, 2010Applicants: KUNMING INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCES, KUNMING INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES, KUNMING JINGBIAO BIOSCIENCES R&D CO., LTD.Inventors: Jijun Chen, Lin Xu, Jun Zhou, Jun Lu, Rongrong Mao, Meng Tian, Qixin Zhou, Xuemei Zhang, Yong Shen, Zhiyong Jiang, Aixue Zuo
-
Patent number: 7763747Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.Type: GrantFiled: November 4, 2008Date of Patent: July 27, 2010Assignee: Proteotech, Inc.Inventors: Alan D. Snow, Beth P. Nguyen, Gerardo M. Castillo, Virginia J. Sanders, Thomas P. Lake, Lesley Larsen, Rex T. Weavers, Stephen D. Lorimer, David S. Larsen, David L. Coffen, Charlotte Coffen, legal representative
-
Publication number: 20100173861Abstract: Compounds, compositions and methods for the treatment of HIV/HSP/HPV, in particular, compositions and methods for a 3 part combination therapy for HIV/HSV/HPV, comprising a viral attachment inhibitor, a viral sequence integration inhibitor, and a proviral transcription inhibitor. The therapy is advantageous for the treatment of HIV infection, and is also effective for HSV and HPV infection. Also disclosed are novel viral attachment inhibitors and methods of use.Type: ApplicationFiled: January 16, 2008Publication date: July 8, 2010Inventors: Ru Chih C. Huang, Ibrahim S. Abd-Elazem
-
Publication number: 20100168045Abstract: The invention concerns novel polyunsaturated compounds of formula (I) wherein: R1 represents a R?1, -A-R?1 group, R?1 being selected from —COOH, —COOR3, —CONH2, —CONHR3, —CONR3, R4, —CHO, —CH2OH, —CH2OR5, and A represents a C2-C16 alkylene, alkenylene or alkynylene; R2 represents: an optionally substituted aryl group or an optionally substituted heteroaryl group; a sugar residue or, a fatty acid residue optionally branched and/or substituted preferably at the chain terminus and particularly by hydroxy, acetoxy radical or by an optionally protected amino radical; a —OC—(CH2)n CO-tocopheryl (alpha, beta or gamma or delta) group, with 2 $m(F) n $m(F) 10; a —R?2—O—R6 group, wherein R?2 is an optionally substituted arylene group or an optionally substituted heteroarylene group, and R6 represents a hydrogen atom, a straight or branched optionally substituted C1-C16 alkyl, a straight or branched optionally substituted C2-C16 alkenyl, or a straight or branched C2-C16 alkynyl group, an optionally substituted tocopheryType: ApplicationFiled: December 14, 2006Publication date: July 1, 2010Applicant: Pierre Fabre Dermo-CosmetiqueInventors: Pascal Bordat, Roger Tarroux, Jean-Hilaire Saurat, Olivier Sorg, Jean-Louis Brayer, Natacha Frison
-
Publication number: 20100129311Abstract: The present invention relates to new phenylalanine amide inhibitors of ATP-sensitive potassium channels, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 23, 2009Publication date: May 27, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventor: Thomas G. Gant
-
Publication number: 20100125103Abstract: Disclosed is a pharmaceutical composition containing obovatol represented by Formula 1 and its derivatives. The obovatol and its derivatives effectively increase the activity of AMPK (AMP-activated protein kinase) that plays an important role in diabetes and metabolic syndrome, and thus may be variously used in treating diabetes and metabolic syndrome. (In Formula 1, R1, R2 and R3 are the same as defined above).Type: ApplicationFiled: June 15, 2009Publication date: May 20, 2010Applicants: TG BIOTECH CO. LTD., KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Tae-Lin Huh, Hebok Song, Ji-Eun Kim, Byoung-Mog Kwon, Dong Cho Han, Hye-Nan Kim
-
Publication number: 20100113497Abstract: In one aspect, the present invention provides a composition of a covalent conjugate of a GABA analog with a drug. In another aspect, the present invention provides methods for treating pain and neurological disorders using the conjugates of GABA analogs.Type: ApplicationFiled: October 8, 2009Publication date: May 6, 2010Applicant: Kyphia Pharmaceuticals, Inc.Inventor: Feng Xu
-
Publication number: 20100104651Abstract: A once-daily controlled-release formulation of diacerein for treating inflammatory or autoimmune diseases or their complications, with reduced adverse side effects and methods of treating such diseases are disclosed.Type: ApplicationFiled: October 28, 2009Publication date: April 29, 2010Inventors: Danchen Gao, Jen-Sen Wu, Wei-Shu Lu, Shouchiung Chen, Pei-Chun Kuo, Chih-Ming Chen
-
Publication number: 20100086494Abstract: The present invention relates to novel carboxylic acid-substituted idebenone derivatives, skin treatment compositions containing these carboxylic acid-substituted idebenone derivatives, methods of treating skin changes by topical application of these carboxylic acid-substituted idebenone derivatives, and their methods of synthesis. The carboxylic acid-substituted idebenone derivatives of the present invention are unexpectedly effective in treating skin, particularly with respect to skin tolerance. When included in a topical composition, the carboxylic acid-substituted idebenone derivatives of the present invention have an antioxidant effect that is useful in treating a skin change.Type: ApplicationFiled: October 6, 2009Publication date: April 8, 2010Applicant: PCR Technology Holdings, LCInventors: Falko Diedrich, Joseph A. Lewis, II, Joseph C. DiNardo, Birgit Neudecker, Eberhard Wieland
-
Patent number: 7687458Abstract: This invention concerns novel methods of enhancing the solubility of a compound. Compositions prepared using such methods are also disclosed. Compositions prepared using the methods have various advantages over conventionally known compositions.Type: GrantFiled: October 11, 2006Date of Patent: March 30, 2010Assignee: Formatech, Inc.Inventors: John G. Augustine, Kaliappanadar Nellaiappan, Benjamin S. Isaacs, Indu J. Isaacs
-
Publication number: 20100069392Abstract: The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the preventive and curative treatment of an inflammatory pulmonary disease.Type: ApplicationFiled: July 3, 2007Publication date: March 18, 2010Applicant: Nycomed GmbHInventor: Stefan-Lutz Wollin
-
Publication number: 20100069326Abstract: The invention is compositions and methods for treating vascular disorders and/or conditions that involve administering a first agent comprising triflusal (or a triflusal analog or derivative) in combination with at least one other active agent.Type: ApplicationFiled: August 14, 2009Publication date: March 18, 2010Inventors: Wasimul Haque, Neil Dunwald
-
Publication number: 20100048651Abstract: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.Type: ApplicationFiled: August 19, 2009Publication date: February 25, 2010Applicant: XenoPort, Inc.Inventors: Archana Gangakhedkar, Xuedong Dai, Noa Zerangue, Peter A. Virsik
-
Patent number: 7667069Abstract: Ibopamine malcate salt (1:1), method for preparing it and pharmaceutical composition containing it.Type: GrantFiled: January 13, 2005Date of Patent: February 23, 2010Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F.S.p.A.Inventors: Mario Pinza, Caterina Maugeri, Nicola Cazzolla
-
Publication number: 20100041748Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.Type: ApplicationFiled: July 8, 2009Publication date: February 18, 2010Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Jesse J. Smith
-
Patent number: 7658937Abstract: A process for the preparation of hydroxyl substituted anthraquinones is described. The process couples a phthalic anhydride (substituted or unsubstituted) to benzene ring moiety substituted with at least two hydroxyl groups. Remaining hydroxy groups were converted to methoxy groups in some anthraquinones. The compounds are particularly useful for the treatment of parasitic diseases. Also, a method of treating or preventing malaria, filariasis schistosomiasis and other parasitic diseases using anthraquinones.Type: GrantFiled: March 7, 2005Date of Patent: February 9, 2010Assignee: Board of Trustees of Michigan State UniversityInventors: Muraleedharan G. Nair, Mugunthu R. Dhananjeyan, Michael A. Kron, Youli P. Milev
-
Patent number: 7652067Abstract: Clear aqueous compositions comprising water, a hydrophobic organic compound, and from about 2 to about 50 wt. % of a solubilizer are disclosed. The solubilizer is an alkali metal or alkaline earth metal salt of a monoester of a saturated C6-C20 alcohol and a saturated dicarboxylic acid. The monoester salts are remarkably effective for solubilizing a wide variety of hydrophobic organic compounds in water to provide aqueous compositions that have excellent stability and outstanding clarity. The compositions are valuable for the cosmetic, agrochemical, coatings, pharmaceutical, and flavor & fragrance industries.Type: GrantFiled: September 8, 2006Date of Patent: January 26, 2010Assignee: Millenium Specialty Chemicals, Inc.Inventors: Mark B. Erman, Joe W. Snow
-
Publication number: 20100004333Abstract: The present invention relates to compounds and methods for the treatment of cardiovascular diseases and disorders. Compounds according to the present invention may comprise an optionally substituted phenyl ring linked to an aromatic or alkyl group by a spacer, wherein the spacer comprises two groups selected from selenium, sulfur, S(O) and S(O)2 and may further optionally comprise an alkylene, alkenylene, cycloalkylene or arylene moiety between the respective selenium, sulfur, S(O) and S(O)2 groups.Type: ApplicationFiled: December 16, 2005Publication date: January 7, 2010Inventor: Roland O. Stocker
-
Publication number: 20090318379Abstract: The present invention relates to methods for the treatment of viral influenza using statins, or pharmaceutically effective salts, pro-drugs or metabolites thereof. In particular it is disclosed that statin hydroxyl acid salts including, but not limited to, mevastatin, lovastatin, pravastatin and simvastatin, are effective in conferring resistance to infection with influenza type A viral challenge.Type: ApplicationFiled: May 4, 2007Publication date: December 24, 2009Inventor: Patrick T. Prendergast
-
Publication number: 20090312411Abstract: The present disclosure provides methods of reducing pregnancy loss or miscarriage in patients by administering compounds that inhibit tissue factor (TF) expression and/or activity on neutrophils and/or monocytes, such as for example, statins, and methods of diagnosing patients having an increased risk of miscarrying.Type: ApplicationFiled: February 9, 2009Publication date: December 17, 2009Applicant: New York Society for the Raptured and Crippled Maintaining the Hospital for Special SurgeryInventors: Guillermina Giradi, Patricia Marie Redecha
-
Publication number: 20090312414Abstract: A method is disclosed utilizing a cannabinoid receptor type 2-receptor-selective agonist for treating or preventing lower urinary tract dysfunction, including overactive bladder, lower urinary tract symptoms and detrusor overactivity.Type: ApplicationFiled: May 14, 2009Publication date: December 17, 2009Applicant: The Procter & Gamble CompanyInventors: Jan Susan Rosenbaum, Karl-Erik Andersson, Iris Alroy
-
Patent number: 7632662Abstract: Carnitines are nutraceuticals with indications in treating a variety of mental health disorders. A metabolomics-guided bioprocess method is presented to produce longer chain fatty acid esters of carnitines such as polyunsaturated fatty acid esters including eicosapentaenoyl-L-carnitine and/or docosahexaenyl-L-carnitine in germinating plant seeds. The resulting products from the plant seeds are used as a natural nutritional source of powerful human antioxidants.Type: GrantFiled: July 31, 2008Date of Patent: December 15, 2009Inventors: Jay W. Pettegrew, Kanagasabai Panchalingam, Richard J. McClure
-
Publication number: 20090286837Abstract: The present invention relates to novel compounds which inhibit urokinase-plasminogen activator (uPA), have a high bioavailability and can be administered orally, and to their use as therapeutic active substances for the treatment of disorders associated with urokinase and/or urokinase receptor, for example tumours and metastasis. The invention relates in particular to compounds containing oxadiazole groups.Type: ApplicationFiled: August 29, 2006Publication date: November 19, 2009Inventors: Stefan Sperl, Jana Zimmermann, Klaus Koch
-
Publication number: 20090285888Abstract: The invention relates to derivatives of dihydroxyphenylalanine, to their synthesis and to pharmaceutical compositions containing said derivatives of dihydroxyphenylalanine. Furthermore, the invention relates to the use of said derivatives of dihydroxyphenylalanine and said pharmaceutical compositions for the treatment and prophylaxis of movement disorders, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, hemiparkinson-hemiatrophy, parkinsonian syndrome, Lewy body disease, frontotemporal dementia, Lytico-Bodig disease (parkinsonism/dementia/amyotrophic lateral sclerosis), striatonigral degeneration, Shy-Drager syndrome, sporadic olivopontocerebellar degeneration, progressive atrophy of the globus pallidus, progressive supranuclear palsy, Hallervorden-Spatz disease, Huntington's disease, X-linked dystonia-parkinsonism (Lubag), mitochondrial cytopathy with striatal necrosis, neuroacanthocytosis, restless legs syndrome, Wilson's disease.Type: ApplicationFiled: May 14, 2006Publication date: November 19, 2009Inventor: Gisela Susilo
-
Publication number: 20090264497Abstract: Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, and some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. The aforementioned active substances may be destabilized by the environmental factors, their degradation may also be accelerated by interactions with other pharmaceutical ingredients, such as fillers, binders, lubricants, glidants and disintegrating agents, therefore the pharmaceutical ingredients and the process for preparation of the pharmaceutical formulation should be meticulously chosen to avoid the aforementioned undesired interactions and reactions.Type: ApplicationFiled: July 11, 2008Publication date: October 22, 2009Applicant: Lek Pharmaceuticals d.d.Inventor: Janez Kerc
-
Publication number: 20090239941Abstract: Compounds of formula (I) are active as dopaminergic compounds or as compounds which or as compounds which diminish the symptoms of dopamine deficiency: wherein: R1 and R2 are independently selected from —C(?O)R5 or —C(?O)OR5; or one of R1 and R2 is hydrogen and the other is —C(?O)R5 or —C(?O)OR5; R3 and R4 are independently selected from hydrogen, optionally substituted C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, or C2-C6 alkynyl, —CH2Q, —C(?O)R5, —C(?O)OR5, —C(?O)NR5R6, or R5 is hydrogen or optionally substituted C1-C6 alkyl or —CH2Q; R6 is hydrogen or optionally substituted C1-C6 alkyl Or —CH2Q; and Q is an optionally substituted monocyclic carbocyclic or heterocyclyl ring of 3 to 6 ring atoms.Type: ApplicationFiled: March 13, 2007Publication date: September 24, 2009Applicant: PROXIMAGEN LTD.Inventor: Christopher Hobbs
-
Patent number: 7589220Abstract: Disclosed are compounds that are anandamide transport inhibitors and their pharmacological use.Type: GrantFiled: July 26, 2004Date of Patent: September 15, 2009Assignee: University of ConnecticutInventors: Alexandros Makriyannis, Andreas Goutopoulos, Chen Li
-
Publication number: 20090221527Abstract: The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-? mediated conditions.Type: ApplicationFiled: January 31, 2006Publication date: September 3, 2009Applicants: CEPTION THERAPEUTICS, INC., TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Mark I. Greene, Ramachandran Murali, Xin Cheng, Raphael Ottenbrite, Yingxin Xiao
-
Publication number: 20090221620Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with vascular diseases such as stroke. In particular, the present invention relates to genetic polymorphisms that have utility for such uses as predicting disease risk or predicting an individual's response to a treatment such as statins, including groups of polymorphisms that may be used as a signature marker set for such uses, as well as nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: February 19, 2009Publication date: September 3, 2009Applicant: Celera CorporationInventors: May Luke, James J. Devlin
-
Publication number: 20090215881Abstract: Cosmetic and therapeutic, in particular dermatological bioprecursors have the formula [A]n—PP—[B]m wherein PP is a polyphenol radical in which each hydroxyl function is protected by a group A or a group B, A is a saturated or unsaturated, substituted or unsubstituted alkyl radical having 1 to 20 carbon atoms which is bonded to the polyphenol, n is an integer not less than 1, and B is a precursor of a biologically active molecule, which is also bonded to the polyphenol, and m is an integer also not less than 1.Type: ApplicationFiled: June 16, 2006Publication date: August 27, 2009Applicants: CHANEL PARFUMS BEAUTEInventors: Sabine Delaire, Adrien Adao, Jean-Roger Desmurs, Mirjana Gelo-Pujic, Laurent Saint-Jalmes, Tarek Kassem
-
Publication number: 20090203774Abstract: The present invention relates to a pharmaceutical composition, a food composition or a cosmetic composition, containing one or more kinds of a compound represented by the following formula (I?) wherein R1 is a hydrogen atom, a hydroxyl group, a methoxy group or an ethoxy group, R2 is a hydroxyl group, a methoxy group or an acetoxy group, or R1 and R2 in combination optionally form a methylenedioxy group, R is represented by the following formula wherein Y is an ethylene group or a vinylene group, m and n are each an integer of 0 to 7, which satisfy m+n=2 to 8, and R3 and R4 are each independently a hydrogen atom, a methyl group or an ethyl group, provided that, (1) when R1 is a methoxy group, then R2 is not a hydroxyl group; and (2) when R1 is a hydroxyl group, then R2 is not a hydroxyl group and an acetoxy group.Type: ApplicationFiled: December 29, 2008Publication date: August 13, 2009Applicant: AJINOMOTO CO., INC.Inventors: Yusuke AMINO, Yoshinobu Takino